New immune therapy trial aims to replace harsh chemo for throat cancer

NCT ID NCT03410615

Summary

This study is testing whether immunotherapy drugs can work as well as or better than standard chemotherapy when combined with radiation to treat a type of throat cancer linked to HPV. It will compare the standard treatment (radiation plus cisplatin chemotherapy) against two approaches using the immunotherapy drug durvalumab with radiation, with one group also receiving an additional immunotherapy drug called tremelimumab. The main goal is to see which treatment best prevents the cancer from coming back over three years while also looking at side effects and quality of life.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OROPHARYNGEAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • AZ Sint Augustinus

    Wilrijk, B-2610, Belgium

  • Allan Blair Cancer Centre

    Regina, Saskatchewan, S4T 7T1, Canada

  • CIUSSS de l'Estrie - Centre hospitalier

    Sherbrooke, Quebec, J1H 5N4, Canada

  • CancerCare Manitoba

    Winnipeg, Manitoba, R3E 0V9, Canada

  • Clinique St. Elizabeth

    Namur, 5000, Belgium

  • Cliniques Universitaires Saint-Luc

    Brussels, 1200, Belgium

  • Complejo Hospitalario de Navarra

    Pamplona, Navarre, 31008, Spain

  • Cross Cancer Institute

    Edmonton, Alberta, T6G 1Z2, Canada

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, 20133, Italy

  • Health Sciences North

    Greater Sudbury, Ontario, P3E 5J1, Canada

  • Hospital Duran i Reynals

    Barcelona, 08907, Spain

  • Juravinski Cancer Centre at Hamilton Health Sciences

    Hamilton, Ontario, L8V 5C2, Canada

  • Kingston Health Sciences Centre

    Kingston, Ontario, K7L 2V7, Canada

  • London Regional Cancer Program

    London, Ontario, N6A 5W9, Canada

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, K1H 8L6, Canada

  • QEII Health Sciences Centre

    Halifax, Nova Scotia, B3H 1V7, Canada

  • Saskatoon Cancer Centre

    Saskatoon, Saskatchewan, S7N 4H4, Canada

  • The Jewish General Hospital

    Montreal, Quebec, H3T 1E2, Canada

  • The Research Institute of the McGill University

    Montreal, Quebec, H4A 3J1, Canada

  • University Clinical Hospital of Valencia

    Valencia, 46010, Spain

  • University Health Network

    Toronto, Ontario, M5G 2M9, Canada

  • University Hospital Leuven

    Leuven, B-3000, Belgium

  • University Hospital Ramon y Cajal

    Madrid, 28034, Spain

  • University Hospital Vall dHebron

    Barcelona, 08035, Spain

  • University Hospital of Antwerp

    Edegem, Belgium

  • University Hospital of Gent

    Ghent, 9000, Belgium

Conditions

Explore the condition pages connected to this study.